Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226431 · ClinicalTrials.gov registry record · Phase 1
Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0
A Phase 1 study of Lung Transplant, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03226431: Completed Phase 1 study of Lung Transplant, sponsored by Duke University.
NCT03226431 is a Phase 1 study of Lung Transplant that has completed, run by Duke University. The registered enrollment target is 6 participants, below the 1,276-participant average among 15 other Lung Transplant trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03226431, a Phase 1 study of Lung Transplant, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
To treat an intermediate size patient population of bilateral lung transplant patients with CLAD-0.
Primary Outcome
Each individual's changes in pulmonary function will be assessed using the linear slope of FEV1 change from enrollment to the end of the treatment period.
Conditions Studied
Interventions
- DRUG Ascorbic Acid
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-12-11 |
| Est. Completion | 2019-06-25 |
| Phase | Phase 1 |
What the finished NCT03226431 record still lists
NCT03226431 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,276-participant average among 15 other Lung Transplant trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Lung Transplant appearing as the primary indexed condition, and to 1 intervention - of which Ascorbic Acid is the first listed.
NCT03226431 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03226431 about?
NCT03226431 is a clinical study titled "Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0". To treat an intermediate size patient population of bilateral lung transplant patients with CLAD-0.
What is the current status of trial NCT03226431?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-12-11. Estimated completion is 2019-06-25.
What conditions does trial NCT03226431 study?
This clinical trial studies the following conditions: Lung Transplant.
What interventions are being tested in trial NCT03226431?
The interventions under investigation include: Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT03226431?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03226431 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03226431's enrollment target sits among peer trials
6 15th of 15 higher than 1 of 15 other Lung Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension
RECRUITING · Phase 1
-
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
RECRUITING
-
Pre-transplant Health Coaching to Improve Patient-Reported Outcomes in Lung Transplant Candidates
RECRUITING · NA
-
Planned Semi-Elective Lung Tx Study
RECRUITING · NA
-
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
RECRUITING · Phase 2
-
Tocilizumab in Lung Transplantation
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI